Clinical Trial Update: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy [Phase 2]

View source ↗

Summary

Phase 2 frontline trial evaluating atezolizumab plus obinutuzumab with or without radiotherapy for follicular lymphoma; current status is active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Olivia Newton-John Cancer Research Institute | Conditions: Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING